Shots:
- Novartis to receive $355M following the closure of acquisition, which is expected to occur in Q2’21. The acquisition expands existing Alcon’s ophthalmic portfolio and strengthens its footprints in the US
- The companies will initiate a transition period where Novartis will continue to sell Simbrinza and transfer the profit to Alcon. Following the transition period, Alcon expects to manufacture & commercialize Simbrinza in the US while Novartis will retain all rights (Ex-US)
- Additionally, Alcon has launched Systane Hydration MDPF lubricant eye drops and is now available in a multi-dose bottle helps to minimize microbial contamination
Click here to read full press release/ article | Ref: Business Wire | Image: Medical Product Outsourcing
The post Alcon to Acquire Exclusive US Commercialization Rights to Novartis’ Simbrinza first appeared on PharmaShots.
